In Vitro Activity of Isavuconazole against a Worldwide Collection of 237 Aspergillus Section Terrei Isolates and Compared with 7 other Aspergillus Active Antifungal Drugs Tested with EUCAST and CLSI Methodology

Ref ID: 18636

Author:

J. F. Meis, MD, PhD – Consultant1,2, J. W. Mouton, MD, PhD – Professor 2, J. P. Bouchara, PhD – Professor 3, A. Chakrabarti, MD – Professor 4, P. Gaustad, MD, PhD – Professor 5, J. V. Guinea-Ortega, PharmD, PhD – Consultant 6, J. Houbraken, PhD – Sen

Author address:

1Canisius-Wilhelmina Hosp., Nijmegen, Netherlands, 2Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3Univ. Angers, Angers, France, 4Postgrad. Inst. Med.Res., Chandigarh, India, 5Univ. Hosp. Oslo, Oslo, Norway, 6Hosp. Gen. Univ. Gregorio Mara

Full conference title:

52nd Annual ICAAC

Date: 9 September 2014

Abstract:

Background: The fungus A. terreus is of concern because of clinical and in vitro resistance to amphotericin B. Here we report in vitro susceptibility of a worldwide collection of 237 Aspergillus section Terrei isolates tested with CLSI and EUCAST methodology for isavuconazole and comparators.
Methods: All isolates had been previously identified as A. terreus by standard morphological procedures at participating centers. Identity was confirmed molecularly using AFLP fingerprinting and ITS sequencing. In vitro susceptibility was performed according to both CLSI and EUCAST.
Results: Typing showed the strain collection tested to be subdivided into A.terreus sensu stricto (n=166), cryptic A. terreus (n=23), A. hortai (n=15) and 12 different closely related species. MIC90s of posaconazole (0.062 µg/ml), itraconazole (0.125 µg/ml), isavuconazole (0.5 µg/ml) and voriconazole (0.5 µg/ml) suggest excellent activity against Aspergillus section Terrei. Amphotericin B had high MIC90s both by CLSI (4 µg/ml) and EUCAST (8 µg/ml). The echinocandins, micafungin (0.031 µg/ml) and anidulafungin (0.004 µg/ml) had low MEC90s. CLSI showed that 100 % of strains had a MIC of <0.5 µg/ml for isavuconazole, compared to 91.5% of strains for voriconazole. Conclusion: The azoles had good in vitro activity and isavuconazole demonstrated similar in vitro activity to voriconazole, the current drug of choice for therapy of aspergillosis.

Abstract Number: M-332

Conference Year: 2012

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster